Investigation of Hsp90 Structure-Activity Relationships in Epigallocatechin Gallate by Patel, Arpita
Montclair State University 
Montclair State University Digital Commons 
Theses, Dissertations and Culminating Projects 
1-2017 
Investigation of Hsp90 Structure-Activity Relationships in 
Epigallocatechin Gallate 
Arpita Patel 
Follow this and additional works at: https://digitalcommons.montclair.edu/etd 
 Part of the Chemistry Commons 
Montclair State University
I Investigation of Hsp90 structure-activity relationships in epigallocatechin gallate/
By
Arpita Patel
A Master’s Thesis Submitted to the Faculty of 
The College of Science and Mathematics 
Montclair State University 
In Partial Fulfillment of the Requirements 
For the Degree of 
Master of Science in Chemistry 
January 2017
College: College of Science and Mathematics 
Department: Chemistry and Biochemistry
Thesis Committee:
Thesis Sponsor: David P. Rotella
Committee Member: David W. Konas
Committee Member: John Siekierka
Abstract:
(-)-Epigallocatechin gallate (EGCG) is a polyphenolic natural product that inhibits the 
key chaperone protein Hsp90 by binding to the carboxy terminal portion of the protein. 
The natural product has modest activity as an Hsp90 inhibitor and there is little 
information in the literature on structure activity relationships for EGCG analogs. 
Previous studies from this laboratory provided initial data on the effect o f a limited range 
of changes associated with functional groups, substituents and stereochemistry. The focus 
of this research is to explore these initial results in more detail with a focus on the 
synthesis of EGCG analogs with more drug like features.
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Introduction
Heat shock proteins (Hsps) are proteins that act as chaperones to help regulate the 
structure and function of other proteins. HSPs are ubiquitously present in normal 
conditions in cells and produced excessively in response to stress.(1,2) This stress can be 
heat, cold, radiation, infection, inflammation, starvation, e tc .(3) Hsps are also upregulated 
in transformed (cancer) cells. This may actually help the tumor cells survive regardless of 
any mutations the cell may have gone through.(1)
Hsp90 is the most abundant heat shock protein in cells. Hsp90 plays a crucial role 
in assembly, maturation, and degradation of many proteins in the body. The proteins that 
depend on Hsp90 for their functionality are referred to as client proteins. Client proteins 
of Hsp90 include SRC family kinases, receptor tyrosine kinases, serine/threonine kinases, 
cell cycle G2 checkpoint kinases, mutant fusion kinases, steroid hormone receptors, 
transcription factors, e tc .(1_4) Many of these client proteins are associated with various 
cancers and neurodegenerative diseases (Alzheimer’s, Huntington’s, and Parkinson’s), 
infectious diseases.(5,6)
There are four isoforms of Hsp90. Hsp90a and Hsp90|3 are cytosolic , Grp94 is 
found localized in the endoplasmic reticulum, and TRAP1 is found in mitochondria.(7)
The cytosolic forms are mainly responsible for maintaining the activity, assembly, 
disposition and turnover of Hsp90 dependent proteins/ client proteins in the cytosol. 
Sidera and colleagues reported that isoforms Hsp90a and Hsp90p are also found on cell 
surface. Surface forms of Hsp90 are associated with migration of cancer cells to sites 
other than its origin.(4) Additionally, each of the isoforms are have targeted functions.
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Therefore, isoform specific inhibition may result in specific biological effects. There
have been a number of studies looking into isoform specific inhibition.(5)
Figure 1: Structure of Hsp90 and Hsp90 dimerization through ATP binding.
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Hsp90 is a dimer (as shown in Figure 1) with each monomer made up of three 
regions: an N-terminal domain, a middle domain/intemal domain, and C-terminal 
domain. Each domain is associated with ATP binding directly. The C-terminal domain 
controls Hsp90 dimerization necessary for functions of the protein. The C-terminus can 
also serve as co-chaperone interaction site. ATP binding in the N-terminal region 
provides the energy necessary for the interaction between Hsp90 and its client proteins as 
well as the energy to promote dimerization. The middle domain contains sites where 
substrate and co-chaperones can bind as well as ATP binding site.(3,5) Hsp90 inhibitors 
targeting each of the regions are being investigated. Most o f inhibitors bind the N- 
terminus, some target the C-terminus, and a few target the internal region. They are 
discussed in more detail in a review article by Bhat and colleagues.(5)
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Hsp90 and its association with cancer
Hsp90 is over expressed in solid tumors and hematologic cancers. Hsp90 interacts 
with many oncoproteins such as Akt, BCR-ABL, EGFR, Raf-1, p53, VEGFR, 
HER2/ErbB2, Src, Cdk4, Cdk6, and cyclin D .(2) These oncoproteins are directly or 
indirectly linked to all six hallmarks of cancers: 1. evasion o f apoptosis, 2. sustained 
angiogenesis, 3. limitless replicative potential, 4. tissue invasion and metastasis, 5. self 
sufficiency in growth signals, and 6. insensitivity to anti-growth signals. Flsp90 allows 
cancer cells to survive and escape apoptosis in hostile and stressful environments, thus 
allowing cancer cells to grow in their mutated forms. Inhibition of Hsp90 function leads 
to degradation of client proteins which can disrupt the survival and growth of cancerous 
cells. Hence, Hsp90 inhibitors can potentially be effective anti-cancer agents.(3)
Hsp90 inhibitors
As a result o f the key role Hsp90 plays in cell growth and division and cellular 
survival, Hsp90 inhibitors have been subject o f interest in medicinal chemistry for almost 
2 decades. Although there are no Hsp90 inhibitors approved for clinical use, many of 
them are and have been in clinical trials. A comprehensive review of Hsp90 inhibitors by
Bhat and colleagues in 2014 provides a recent update on clinical and preclinical research.
(5)
Hsp90 inhibitors that are currently being investigated can be categorized as (5):
1. N-terminal inhibitors
- Natural products and derivatives (benzoquinone, radicicol)
Synthetic small molecules and peptide derivatives 
• Purine based Inhibitors
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• Isoxazole and triazole derivatives
Isoform selective inhibitors
2. Allosteric modulation o f Hsp 90 : inhibits client proteins from binding Hsp90
3. C-terminal inhibitors
- Novobiocin and analogs 
EGCG and analogs
This research project is focused on synthesis of novel EGCG derivatives. The 
following paragraphs provide useful background information and summarize what is 
known about structure activity relationships for Hsp90 inhibition in EGCG and analogs.
Figure 2: Structure of EGCG
OH
(-)-Epigallocatechin gallate (EGCG) is the most abundant polyphenol/flavanoid 
found in green tea. It has been the subject o f wide ranging investigations related to 
potential utility in the treatment of inflammatory diseases, cancer, viral and neurological 
conditions.(8,9) The potential of EGCG as an Hsp90 inhibitor and its mode of action by 
binding to the C-terminus were first reported by Gasiewicz and coworkers in 2009.(10) 
Inhibition of Hsp90 leads to degradation of its client proteins; leading to downstream
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signaling inhibition, and loss of client protein function.(5) The precise binding site on 
Hsp90 for EGCG is not known however the region in the C terminus has been localized 
to amino acids 538-728 on H sp90.(11)
EGCG has multiple structural features that contribute to unsatisfactory drug like 
properties. Multiple phenolic hydroxyl groups contribute to oxidative and chemical 
instability in solution as well as metabolic instability. These hydroxyl groups also 
significantly increase the polarity of EGCG that can reduce cell permeability and oral 
absorption. The ester moiety is labile to hydrolysis by plasma esterases(8) As a result of 
these issues, our interest is focused on investigating structural modifications to EGCG 
that will improve one or more of these characteristics, while at the same time improving 
the affinity o f the molecule for Hsp90. Previous work from Dr. Brian Blagg’s research 
group and our laboratory reported initial studies toward this objective.(5, n)
Figure 3: EGCG (1) and EGCG analog (2) (Khandewal and coworkers)
OH
Structure activity studies on EGCG have been done on méthylation and deletion 
of phenolic hydroxyl moieties. A study by Khandewal and group that investigated the 
activity of EGCG analogs against breast cancer cells showed that A-ring (shown in
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Figure 3) hydroxyl groups are required and elimination of B-ring (Figure 3) hydroxyl 
groups can be advantageous for anti-cancer activity. Removing all hydroxyl group on the 
C-ring, and replacing them with different R groups in compound 2 (IC50 4 pM) improved 
activity by 18 fold compared to EGCG (IC50 74 pM) when tested against MCF-7 breast 
cancer cell lines.(11)
Previous studies on Hsp90 inhibition S AR of EGCG analogs done by our research 
group is summarized in Table 1. Comparison of the activity o f 1 (EGCG, IC50 155 pM) 
to 3d (amide, IC50 75 pM) and 3e (sulfonamide, IC50 44 pM) shows that replacing the 
ester in EGCG with other functional groups can improve Hsp90 inhibition. These 
moieties are less likely to be hydrolytically cleaved which may improve compound 
stability.Furthermore, a number of derivatives lacking one or more phenolic hydroxyl 
groups including 3b (IC50 24 pM), 3h (IC50 63 pM), and 3i (IC50 35 pM) show improved 
potency compared to EGCG. Fluoro substitution as in 3c (IC50 41 pM) also gives more 
potent Hsp90 inhibition, compared to EGCG. The activity of 3a (trans, IC50 34 pM) was 
improved compared to EGCG suggesting that trans-orientation of substituents on the 
pyran ring may also improve Hsp90 inhibition. The aromatic D ring can be replaced by 
cyclohexane as shown in 3f (IC50 81 pM) and 3g (IC50 155 pM) to increase potency as an 
Hsp90 inhibitor.(5)
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Table 1: Summary of SAR of EGCG analogs for HSP90 inhibition by Bhat and 
colleagues.
R3
# Cis/
trans3
Ri r2 r3 R4 Rs X Y z ICso
(HM)
1 Cis OH OH OH OH OH 0 c=o Gallate 155
3a Trans OH OH OH OH OH 0 c=o Gallate 34
3b Cis OH OH OH OH OH 0 c=o Phenyl 24
3c Cis OH OH OH OH OH 0 c=o 4-F-Phenyl 41
3d Cis OH OH OH OH OH N c=o Phenyl 75
3e Cis OH OH OH OH OH N so2 Phenyl 44
3f Cis OH OH OH OH H 0 c=o Cyclohexane 81
3g Cis OH OH OH OH H 0 c=o 4-F-cyclohexane 65
3h Cis OH OH H H H 0 c=o Phenyl 63
3i Cis H H H H H 0 c=o Gallate 35
a B ring/ X absolute stereochemistry for 3a-3g; and relative stereochemistry for 3h-3i
The design of new targets for this research project was based on the observations 
summarized above. New EGCG analogs were synthesized in which the metabolically 
labile ester was replaced with amide or sulfonamide, all the phenolic hydroxyl groups 
were removed and/or replaced by fluorine or chlorine. The D-ring was also replaced with 
small aliphatic methyl group in few compounds. To investigate the effect of
stereochemistry on Hsp90 inhibition, cis and trans isomers o f each molecule were 
synthesized. All of the target molecules are shown in Figure 4.
Figure 4: All target molecules
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Chemistry
Retro synthesis
Figure 5: This figure demonstrates different ways to synthesize key cis and trans amines 
that will be used for amide and sulfonamide synthesis
17 16 5
OH
The objective of this research is to extend and develop existing structure activity 
relationships in this series of Hsp90 inhibitors to explore additional features that might 
contribute to activity. The modifications that were made were removal of phenolic
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hydroxyl groups on A ring and B ring and D ring (refer to Figure 2 to see compound 1), 
replacing the para hydroxyl group on B ring with fluorine, replacing ester group linking 
C and D ring with amides and sulfonamides, and adding halogen groups on D ring or 
substituting D-ring with a small aliphatic group (methyl). This sequence will also permit 
us to investigate the role of stereochemistry (cis/trans on the chromene ring) in potential 
Hsp90 inhibitor.
Amide and sulfonamide target molecules will be prepared from the corresponding 
amine. As indicated in Figure 4, three different routes can be investigated to the key 
amine (trans 19 or cis 20). One begins with aldol condensation o f ketone 4 and aldehyde 
5 followed by ring closure and dehydration to furnish olefin 9. An alternative route to 9 
begins with vinyl bromide 12 and tosyl hydrazone 15. Each of these can furnish 
hydroxyl chroman 9a that can be converted to amine (19 or 20) by displacement or 
reductive animation. The third approach employs a condensation reaction between vinyl 
nitro compound 16 and salicaldehyde 5 to lead to nitro chromene 17. This intermediate 
can be reduced to furnish key amine (19 or 20).
12
Synthesis
Route 1
Scheme 1: Reagents and conditions: a) NaOH, EtOH, rt, 24hrs; b) KF, MeOH, reflux, 
o/n; c) NaBFL*, EtOH, rt, 2hrs; d) R-SO3CI, Base*. (*The conditions for this step are 
described in Table 2 in more detail)
The EGCG analogs for this research were prepared synthetically. The first step 
was to prepare the bicyclic chromene ring system. A base catalyzed Claisen-Schmidt 
condensation reaction between 2-hydroxyacetophenone (5) and 4-fluorobenzaldehyde 4 
in ethanol was used to synthesize chalcone 6. Attempt to make chromene 9 from 6 using 
NaBH4 in different solvent systems failed. Therefore, an alternative route (shown in route 
1 scheme) was chosen to synthesize chromene 9. Using KF as catalyst, 6 was isomerized/ 
cyclized to 7 in methanol. Ketone in 7 was reduced to alcohol in 8 using NaBH4 in 
ethanol.(12)
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Table 2: Different reaction conditions to synthesize 9 from 8
Trial Base R-SO2CI Temperature Time Yield (%)
1 Et3N Me Rt 4 hrs 16
2 Et3N Me 40°C o/n 11
3 Diisopropylethylamine Me Rt o/n 2
4 Diisopropylethylamine Me 40°C o/n 2.5
5 Et3N Me Rt o/n 6.5
6 DBU p-toluene Rt 3 days 6
Dehydration/elimination of 8 was carried out using base and methanesulfonyl 
chloride. Different bases such as triethylamine, diisopropylethylamine and morpholine 
were investigated to optimize this reaction. However, the yield in each instance was 
unacceptably low. Therefore, this approach to synthesis of EGCG analogs was dropped.
Route 2
Scheme 2: Reagents and conditions: e) Mn(0 Ac)2.4 H2 0 , H2 0 :ACN, rt, 2hrs; f) MeOH, 
reflux, 2 hrs; g) Pd2(dba)3.CHCl3, PCy^HBF^ K2CO3, Anhydrous dioxane, 100°C, o/n
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In an alternative approach to obtain chromene 9, we needed to synthesize 12 and 
15. Hunsdiecker reaction with triethyl amine as a catalyst, 4-fluoro cinnamic acid 10 and 
N-bromosuccinamide 11 as starting material was not successful.(13) An alternative 
approach that employed manganese acetate hydrate with the same starting materials 
furnished 12 via bromodecraboxylation.(14) Nucleophilic addition of tosyl group from 4- 
methylbenzenesulfonylhydrazide 14 to salicylaldehyde 13 in methanol leads to synthesis 
of 1 5 .(15) Palladium catalyzed coupling reaction between 12 and 15 was used to 
synthesize 9 . (16) This method afforded an improved yield (52%) of chromene 9 compared 
to route 1. However, the reaction also produced a number of side products and the 
catalyst required is expensive. Therefore, this method was also eliminated.
Route 3
In another approach, base catalyzed Michael addition was used to synthesize 16 
from 4-fluorobenzaldehyde 5 and nitromethane.(17) This is similar to aldol addition. 
Cyclocondensation followed by Oxa-Michael addition between 16 and salicylaldehyde 
(13) was used to synthesize 17. 4-Nitrobenzoic acid and pyrrolidine were used as 
catalysts.(18) The olefin in 17 was easily reduced using NaBH4 in methanol to form 18.
(19) The nitro group in 18 was selectively reduced to trans amine 19 using activated Zn.
(20) Synthesis of cis amine 20 was carried out using diborane in THF and sodium 
borohydride.(21) Each of these reductions was highly stereocontrolled to provide the 
desired isomer in good yield. Both, cis and trans, amines were synthesized as a racemic 
mixture of diastereomers, since they were synthesized from non-chiral starting materials. 
Thus, all the compounds synthesized using these two amines acquire relative 
stereochemistry rather than absolute stereochemistry.
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Scheme 3a: Reagents and conditions: h) I. M eN 02, aq. NaOH, MeOH, 0°C, 1 hr; II. aq. 
HC1, 0°C, 10 mins; i) I. 4-nitrobenzoic acid, pyrrolidine, MeOH, rt, 1 hr; II. reflux, o/n; j) 
NaBH4, THF:MeOH, 0°C, 2 hr; k) I. activated Zn, 1M HCkIPA, 60°C, 2 hrs; II. 
N aHC02, rt, 10 mins; 1) BH3:THF, NaBH4, 0°C- 70°C, o/n
We confirmed the stereochemistry o f each amine by comparing the resonance 
signals and coupling constants for the methine proton alpha to the amine. The proton 
NMR of 19 (trans amine) shows a trans diaxial coupling constant of 8.6 Hz with the 
adjacent proton at alpha position to phenyl. For 20 (cis amine), the coupling constant of 
the same proton is 1.9 Hz, which is evident of axial-equatorial coupling. These coupling 
constants are consistent with the literature values for the coupling constants for similar 
cis and trans compounds.(22) Additionally, the axial proton (alpha to amine) in trans 
amine shows up more upheld (at 3.15 ppm) compared to the equatorial proton (alpha to 
amine, shows up at 3.43 ppm).
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Scheme 3b: Reagents and conditions: m) R-COOH, EDCI.HC1, DMAP, DCM, rt, o/n; 
n)R-S02Cl, Et3NH2, DCM, rt, o/n
19 or 20
Table 3: List of amides
Compound Stereochemistry R % yield
21a Trans 4-F Phenyl 68
21b Trans Phenyl 66
21c Trans c h 3 73
21d Trans 4-C1 Phenyl 83
21e Cis 4-F Phenyl 75
21f Cis Phenyl 56
21g Cis c h 3 62
21h Cis 4-C1 Phenyl 85
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The final step is a simple coupling reaction between amine and carboxylic acid, 
and amine and sulfonyl chloride. Amine and carboxylic acid coupling forms amides; and 
amine and sulfonyl chloride coupling makes sulfonamides. All the amides and 
sulfonamides that were synthesized are listed in Table 3 and Table 4 respectively.
Table 4: List of sulfonamides
Compound Stereochemistry R % yield
22a Trans 4-F Phenyl 87
22b Trans Phenyl 52
22c Trans Methyl 84
22d Trans 4-C1 Phenyl 55
22e Cis 4-F Phenyl 72
22f Cis Phenyl 82
22g Cis Methyl 72
22h Cis 4-C1 Phenyl 76
Results and discussion:
The synthesis of EGCG analogs (21 a-h and 22a-h) with structural modifications 
are described in scheme 3. Selected compounds (21a, 21b, 2 le, 2 If, 22a, and 22e) were 
sent to Dr. Brian Blagg’s research group at the University of Kansas to be tested for 
Hsp90 inhibition using standard luciferase based readout.(23) These compounds were
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tested at concentration of 10 pM for inhibition of Hsp90-dependent firefly luciferase 
refolding in PC3 cells. Preliminary results o f this assay are shown in the table below. 
IC50S values are still pending.
Table 5: Summary of the activity of the compounds tested for Hsp90 activity.
Compound Cis/trans Amide/
Sulfonamide
R % refolded
21a Trans A 4-F Phenyl 42
21e Cis A 4-F Phenyl 110
22a Trans S 4-F Phenyl 24
22e Cis S 4-F Phenyl 76
21b Trans A Phenyl 64
21f Cis A Phenyl 97
As shown in table 5, compound 21a shows greater Hsp90 inhibition (42%) 
compared to 21 e (110%) which indicates that compounds with trans stereochemistry 
shows higher inhibition compared than cis compounds. Similarly, while comparing 22a 
(trans, 24%) versus 22e (cis, 76%) and 21b (trans, 64%) versus 2 I f  (cis, 97%), one can 
see the trend o f trans molecule having higher activity. Furthermore, sulfonamide 
compounds 22a (24%) and 22e (76%) exhibit better Hsp90 inhibition compared to their 
amide analogs 21a (42%) and 21e (110%). In a very limited manner, we investigated 
substituent effects in the phenyl ring in which fluoro substitution was compared to 
hydrogen. There is insufficient information to draw a conclusion or identify trends from 
the compounds evaluated in this study.
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Experimental section:
All reactions were monitored using thin layer chromatography using silica gel and 
were visualized using ultraviolet light. All extractions were performed 3 times with 
appropriate amounts of solvents. All reaction products were analyzed using lH and/or 13C 
NMR which were obtained using a 300 MHz or 400 MHz Bruker spectrometer. All NMR 
samples were prepared in CDCI3 unless stated otherwise; chemical shifts are reported in 
ppm. Final compounds were analyzed using Schimadzu LCMS 2020 and Acquity UPLC. 
Schimadzu LCMS 2020 used Schimadzu Cig 3pm, 4.6 x 50 mm column , water and 
methanol as solvents (50% water-50% Methanol to 90% Methanol-10% water in 5 
minutes) at flow rate of 0.5 mL/min, and detection wavelength 220 and 254 nm. Aquity 
UPLC used Acquity UPLC BEH C% 1.7 pm, 2.1 x 100 mm column, water and acetonitrile 
as solvents (90% water-10% acetonitrile to 90% acetonitrile-10% water in 6 minutes) at 
flow rate 0.4 mL/min, and detection wavelength 254 nm (or 230 nm when mentioned).
All target compounds (amides and sulfonamides) showed at least > 97% purity by NMR 
and UPLC analysis.
Route 1
F
O
6
6: NaOH (7.34g, 4eq) solution (solid dissolved in 10 mL of water) was gradually added 
to the mixture of 2-hydroxyacetophenone 4 (lOg, 1 eq) and 4-fluorobenzaldehyde 5 
(9.97g, 1.1 eq) in ethanol (150 ml) at room temperature and stirred at room temperature
20
overnight. The reaction mixture was poured over ice to crystallize the product. 1M HC1 
was added to this mixture. Precipitated product was filtered and solid product was 
dissolved in dichloromethane, washed with brine and dried over sodium sulfate. Solvent 
was removed from the product by rotary evaporation; and product was purified using 
flash column chromatography (0-20% ethyl acetate in hexanes) to afford a yellow solid. 
(15.1g, 85% yield) 'H NMR (300 MHz, CDCI3) 8 12.80 (s, 1H), 7.96 -  7.85 (m, 2H), 
7 .7 1 -7 .6 4  (m, 2H), 7.60 ( d ,J =  15.5 Hz, 1H), 7.52 (ddd ,./=  8.6, 7.2, 1.7 Hz, 1H), 7.19 
-7 .1 0  (m, 2H), 7.05 (d d ,J=  8.4, 1.2 Hz, 1H), 6.96 (ddd, 8.3, 7.2, 1.2 Hz, 1H).
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7: 6 (lOg, leq) was dissolved in methanol (150 mL) with heating. KF (1.2g, 0.5 eq) was 
added to the mixture and the mixture was refluxed overnight. Reaction mixture was 
concentrated and dissolved in ethyl acetate then was washed with brine and dried over 
sodium sulfate.(12) The light yellow solid obtained following removal of solvent by rotary 
evaporation was used without further purification (9.7g, 97% yield). !H NMR (300 MHz, 
CDC13) 6 7.98 -  7.91 (m, 1H), 7.57 -  7.45 (m, 3H), 7.14 (ddt, J=  8.7, 6.6, 2.5 Hz, 2H),
7.11 -  7.04 (m, 2H), 5.48 (dd, J=  13.2, 3.0 Hz, 1H), 3.08 (dd, J=  16.9, 13.2 Hz, 1H),
2.89 (dd, J=  16.8,3.0 Hz, 1H); 13C NMR (75 MHz, CDC13) 6 191.77, 164.49, 161.42, 
161.21, 136.32, 134.64, 134.60,128.12, 128.01, 127.12, 121.80, 120.92, 118.12, 115.99, 
115.70, 78.96, 44.71.
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88: NaBH4 (1.46g, 2 eq) was added to 7 (4.7g, 1 eq) dissolved in EtOH (100 mL) at 0° C. 
Reaction mixture was brought to room temperature and stirred for 2 hours. 10 mL of 
acetone was added to the reaction mixture over 30 minutes period (2 ml at a time) to 
quench excess NaBtLj. The reaction mixture was concentrated and dissolved in distilled 
water. This solution was extracted with ethyl acetate. The collected organic extract was 
washed with brine and dried over sodium sulfate. The solvent was removed by rotary 
evaporation to provide an off white solid .(12) (4.7g, 97 % yield). !H NMR (300 MHz 
CDCI3) 5 7.54 (dt, J=  7.7, 1.4 Hz, 1H), 7.48 -  7.40 (m, 2H), 7.26 -  7.19 (m, 1H), 7.14 -  
7.07 (m, 2H), 7.01 (td, J=  7.5, 1.3 Hz, 1H), 6.90 (dd, J=  8.3, 1.2 Hz, 1H), 5.22 -  5.08 
(m, 2H), 2.52 (ddd, 13.1, 6.3, 2.0 Hz, 1H), 2.13 (ddd, J=  13.1, 11.7, 10.5 Hz, 1H).
9: 8 (O.lg, 1 eq) was dissolved in dichloromethane (3ml) and the base (3 eq) was added to 
the mixture. Reaction mixture was cooled down to 0° C. Sulfonyl chloride (1.2 eq) was 
added to the mixture at 0° C. Reaction mixture was brought back to room temperature or 
40° C (see the table 2 for clarification) and stirred. Reaction mixture was washed with 
ammonium chloride solution to remove access base. Collected organic layer was diluted 
in distilled water. This solution was washed with brine and dried over sodium sulfate.
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Organic layer was concentrated and purified using flash column chromatography (0-20 % 
ethyl acetate in hexanes) to afford a clear liquid. (See Table 2 for yields). [H NMR (300 
MHz, CDC13) 5 7.44 (ddd, 7 =  8.7, 4.9, 2.2 Hz, 2H), 7.17 -  7.12 (m, 1H), 7.12 -  7.01 (m, 
4H), 6 .9 3 -6 .8 5  (m, 1H), 6.78 (dt, 7 = 8 .3 , 1.0 Hz, 1H), 6.57 (ddd, 7  = 9.9, 1.9, 0.8 Hz, 
1H), 5.91 (dd, 7  = 3.5, 1.9 Hz, 1H), 5:79 (dt, 7 =  9.9, 2.8 Hz, 1H).
Route 2
12
12: N-Bromosuccinimide 11 (0.187g, 1.05eq) and manganese (II) acetate (0.049g, 0.2 eq) 
were added to 4-fluorocinnamic acid 10 (0.166g, 1 eq) in water (3 mL) and acetonitrile (3 
mL) solvent mixture. Reaction mixture was stirred at room temperature for 2 hours. 
Reaction mixture was diluted in excess distilled water; and the product was extracted in 
ethyl acetate. The collected organic layer was washed with brine and dried over sodium 
sulfate. The organic layer was concentrated (using rotary evaporation); and product was 
purified using flash column chromatography (0-40% ethyl acetate in hexane) to afford an 
off white pow der.(14) (0.129g, 64% yield). lH NMR (300 MHz, CDC13) 6 7.33 -  7.23 (m, 
2H), 7.12 -  6.98 (m, 3H), 6.75 -  6.66 (m, 1H).
H
15
15: 4-methanebenzenesulfonehydrozole 14 (1.22g, 1 eq) was added to salicylaldéhyde 13 
(1.86g, leq) in methanol (50 mL). Reaction mixture was refluxed for 2 hours. The
23
solvent was removed by rotary evaporation, and the product was washed with 
dichloromethane and hexanes to remove methanol from the product. All solvents were 
removed using rotary evaporation to afford a white solid.(15) (2.72g, 94%). *H NMR (300 
MHz, DMSO-J6)5  11.45 (s, 1H), 10.19 (s, 1H), 8.16 (s, 1H), 7 .7 7 -7 .7 0  (m, 2H), 7 .4 8 -  
7.38 (m, 3H), 7.22 (ddd, J=  8.4, 7.3, 1.8 Hz, 1H), 6.87 -  6.78 (m, 2H), 2.35 (s, 3H).
F
9
9: Pd2(dba)3.CHCl3 (0.093g, 2.5%), PCy3.HBF4 (0.198g, 15%), K2C 0 3 (1.49g, 3eq) and 
15 (2.08g, 2 eq) were added to an oven dried flask under anhydrous conditions. 
Anhydrous dioxane (10 mL) was added to the mixture. Then, 12 (0.72g, leq) was added 
to the reaction mixture. Reaction mixture was heated at 100°C and stirred overnight 
under anhydrous conditions. Reaction mixture was cooled to room temperature and 
filtered through diatemateaous earth to remove all solid side products and reagents 
including Pd catalyst. Reaction mixture was concentrated and then diluted in ethyl 
acetate. Reaction mixture was washed with water and then extracted in ethyl acetate. The 
collected organic layer was washed with brine and dried over sodium sulfate. The organic 
layer was concentrated; and flash column chromatography (0-20% ethyl acetate in 
hexanes) was used to purify the product to a thick cloudy orange liquid.(16) (0.42g, 52%) 
‘H NMR (400 MHz, CDCI3) 6 7.48 -  7.43 (m, 2H), 7.14 (td, J=  7.7, 1.7 Hz, 1H), 7.10 -  
7.03 (m, 3H), 6.90 (td, J =  7.4, 1.1 Hz, 1H), 6.80 (dd, J =  8.1, 1.1 Hz, 1H), 6 .58(dd ,./ = 
9.9, 1.9 Hz, 1H), 5.92 (dd, 7 =  3.4, 1.9 Hz, 1H), 5.80 (dd, 9.8, 3.4 Hz, 1H).
Route 3
24
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16: NaOH (7.5g, 2.5eq), dissolved in small amount of water, was gradually added to the 
mixture o f 4-Fluorobenzaldehyde 5 (9.16g, 1 eq) and nitromethane (11.44g, 2.5 eq) in 
methanol (120 mL) at 0° C. Reaction mixture was stirred at 0° C for 1.5 hours. Some 
crushed ice was added to the mixture. Then, the reaction mixture was poured over 
vigorously stirring 5M HCL (100 mL) solution at 0° C. Off white colored solid product 
precipitates in the solution as the mixture is stirred for few minutes. Precipitated product 
was vacuum filtered and washed with distilled water. The product was air dried to afford 
an off white pow der.(17) (5.96g, 65%). *H NMR (400 MHz CDCI3) 8 7.99 (dd, J -  14.3, 
4.9 Hz, 1H), 7 .62-7 .51  (m, 3H), 7.17 ( tq , /=  8.2, 2.7 Hz, 2H); 13CNM R(101 MHz, 
CDCI3) 5 166.21, 163.67, 137.85, 136.86, 131.36, 131.27, 126.35, 126.31, 116.90,
116.68.
F 
17
17: 16(1.67g, 0.95 eq) was added to a solution mixture of 4 nitrobenzoic acid (0.44g, 0.25 
eq) and pyrrolidine (0.185g, 0.25 eq) in chloroform (20 mL) at room temperature. This 
mixture was stirred at room temperature for 1 hour. Then, salicyladlehyde (1.28g, leq) 
was added to the reaction mixture and the reaction mixture was refluxed overnight. 
Reaction mixture was cooled down to room temperature and diluted in distilled water. 
Product was extracted in chloroform. The collected organic layer was washed with brine
25
and dried over anhydrous sodium sulfate. Dry organic layer was concentrated (using 
rotary evaporation) and purified using flash column chromatography (0-20% ethyl acetate 
in hexanes) to afford a yellow solid .(18) (2.47g, 90%) ]H NMR (400 MHz, CDCI3) 8 8.08 
(d, J=  0.9 Hz, 1H), 7.42 -  7.31 (m, 4H), 7.06 -  6.98 (m, 3H), 6.90 -  6.85 (m, 1H), 6.57 
(s, 1H); 13C NMR (101 MHz, CDC13) 5 164.53,162.05,153.32,141.06,134.45,132.76,
132.74,130.48,129.35,129.04, 128.97,122.70, 117.83,117.31,115.98,115.76, 73.57.
F
18
18: 17 (2.35g, leq) was dissolved in methanol (25 mL) and THF (15 mL) and cooled 
down to 0°C. NaBHU (0.49g, 1.5 eq) was gradually added to the mixture in fractions over 
10 minutes. Reaction mixture was stirred at 0°C for 2.5 hours. The solvents were 
removed using rotary evaporation. The reaction mixture was diluted in ethyl acetate and 
washed with NH4CI and NaHCC>3 to remove side products. Then it was washed with 
water. The aqueous layer was extracted with ethyl acetate. The collected organic layers 
were combined, washed with brine and dried over anhydrous sodium sulfate.(19) The 
solvent was removed using rotary evaporation. Majority of the product was recrystallized 
in 50% ethyl acetate in hexane solvent mixture to afford a white crystals. The leftover 
solvent was concentrated and purified using flash column chromatography (0-30% ethyl 
acetate in hexanes) to afford a white solid. The products from recrystallization and 
chromatography were combined (1.5g, 63%). !H NMR (400 MHz, CDCI3) 8 7.47 -  7.36 
(m, 2H), 7.27 -  7.21 (m, 1H), 7.18 (dd, J=  7.6, 1.4 Hz, 1H), 7.16 -  7.07 (m, 2H), 7.02 
(td, J=  7.4, 1.2 Hz, 1H), 6.98 (dd, J=  8.2, 1.2 Hz, 1H), 5.36 (d ,J =  8.4 Hz, 1H), 5.02
26
(ddd, J=  10.0, 8.4, 5.5 Hz, 1H), 3.70 (dd, J= 16.1, 9.9 Hz, 1H), 3.38 (dd, 16.2,5.5
Hz, 1H); 13C NMR (75 MHz, CDC13) 5 164.95, 161.66, 153.18, 131.51, 131.46, 129.38, 
128.96,128.85, 128.58, 122.10,117.63, 117.02,116.18,115.89, 84.21,30.22.
19: Fine Zn powder was activated by stirring the Zn powder in 1M HC1 for 1 hour. After 
1 hour activated Zn was filtered, washed with ether and placed in oven to dry for 30 
minutes. Activated Zn (l-2eq) was added to 18 suspended in isopropanol (40 mL) and 
1M HCL (20 mL) solvent mixture. This mixture was stirred at 60°C for 2 hours. Then, 
NaHCC>3 solution (25 mL) was added to the reaction mixture and the mixture was stirred 
for additional 20 minutes. The reaction mixture was concentrated and extracted with 
dichloromethane. The collected organic layer was washed with brine and dried over 
sodium sulfate. The solvent was removed using rotary evaporation and flash column 
chromatography was used to purify the product (0-100% ethyl acetate in hexanes) to 
afford a white solid.(20) (0.38g, 57%) ‘H NMR (400 MHz, DMSO-<76) 6 7.49 -  7.43 (m, 
2H), 7.27 -  7.20 (m, 2H), 7.10 (ddd, J=  13.3, 7.5, 1.6 Hz, 2H), 6.86 (td, 7.4, 1.2 Hz,
1H), 6.79 (dd, J =  8.0,1.2 Hz, 1H), 4.64 (d, J=  8.6 Hz, 1H), 3.15 (ddd, 10.1,8.5,5.1
Hz, 1H), 2.91 (dd, J =  16.3, 5.2 Hz, 1H), 2.66 (dd ,J=  16.2, 10.1 Hz, 1H); 13CNM R(101 
MHz, DMSO-<4)8 163.54,161.12,154.61, 136.10,130.09,130.02,127.63, 122.11, 
120.88, 116.29, 115.68, 115.46, 83.09,49.48, 34.23; MS (ESI+) m/z calcd 243.11, found 
[M + H+] 244.00.
27
20
20: 1 M borane (16 mL,4 eq) in THF was slowly added to 17 dissolved in anhydrous 
THF at anhydrous conditions at 0°C in an oven dried flask. The reaction mixture was 
brought to room temperature and NaBH4 (0.076g, 0.5eq) was added to the reaction 
mixture at room temperature. Reaction mixture was stirred at room temperature for 10 
minutes. Then it was heated up to 65-70 °C and stirred overnight at that temperature. 
Reaction mix was cooled down to room temperature and some ice water was added to it. 
1M HCL was added to the reaction mixture to make pH approximately 2. Reaction 
mixture was stirred at 65 °C for 2 hours. Reaction mixture was cooled to room 
temperature and the acidified solution was extracted with ether. The aqueous layer was 
basified to pH ~12 by adding some 6M NaOH solution. Basified aqueous layer was 
extracted with ethyl acetate. Ethyl acetate layer was washed with brine and dried over 
sodium sulfate. Ethyl acetate layer was concentrated and flash column chromatography 
was used to purify the product (0-100% ethyl acetate in hexanes) to afford clear liquid 
product.<21) (0.67g, 61%). 'H NMR (400 MHz, DM SO -*) 5 7.53 -  7.46 (m, 2H), 7.26 -  
7.20 (m, 2H), 7.13 (t , J=  7.0 Hz, 2H), 6.89 (dd, J=  7.8, 6.5 Hz, 2H), 5.20 (d, J=  1.8 Hz, 
1H), 3.43 (ddd, J  = 5.0, 3.1, 1.9 Hz, 1H), 3.22 (dd, J  = 16.4,4.9 Hz, 1H), 2.65 (dd, J=
16.4, 3.2 Hz, 1H); 'H  NMR (400 MHz, MeOD) 5 7.52 (ddd, J  = 9.9, 5.4, 2.5 Hz, 2H), 
7.16 (ddt, J=  12.6,10.4, 4.4 Hz, 4H), 6.98 -  6.86 (m, 2H), 5.18 (s, 1H), 3.49 -  3.39 (m, 
1H), 3 .3 9 -3 .3 0  (m, 1H), 2 .7 8 (d t,J=  15.3,4.0 Hz, 1H); 13C NMR (101 MHz, MeOD) 5
28
153.97, 130.09, 127.62, 127.62, 127.16, 120.91, 119.26, 116.22, 114.85, 114.63,78.09, 
32.73; MS (ESI+) m/z calcd 243.11, found [M + H+] 244.00
Amide (21)
Table 6: List of Amides and their yields. (* Carboxylic acid was not used for this 
experiment. Acetic anhydride was used as a source o f methyl ester)
Compound Stereochemistry Carboxylic acid % yield
21a Trans 4-F Phenyl 68
21b Trans Phenyl 66
21c Trans Acetic anhydride* 73
21d Trans 4-C1 Phenyl 83
21e Cis 4-F Phenyl 75
21f Cis Phenyl 56
21g Cis Acetic anhydride* 62
21h Cis 4-C1 Phenyl 85
General procedure to synthesize amides:
Amine (19 or 20) (leq), Carboxylic acid (2 eq), EDCI.HC1 (2.1 eq), 
dimethylaminopyridine (0.4 eq) and dichloromethane were mixed in an RBF and stirred 
overnight at room temprature. The reaction mixture was diluted in dichloromethane and 
washed with 1M HC1. The collected organic layer was first washed with distilled water, 
then with brine and then dried over anhydrous sodium sulfate. The organic layer was 
concentrated and purified using flash column chromatography (0-60 % gradient of ethyl
29
acetate in hexanes) to afford a white powder. (Refer to Table 6 for yields o f all the 
amides that were synthesized)
21a: 'H NMR (400 MHz, CDCI3) 8 7.75 -  7.69 (m, 2H), 7.43 -  7.37 (m, 2H), 7.32 -  7.27 
(m, 1H), 7.15 -  7.06 (m, 6H), 7.00 (td, J=  7.4, 1.4 Hz, 1H), 6.37 (d ,./=  8.3 Hz, 1H), 5.47 
(d, J=  3.9 Hz, 1H), 4.88 (dq, J=  8.6, 4.4 Hz, 1H), 2.98 (dd, J=  16.7, 4.9 Hz, 1H), 2.86 
(dd, J=  16.7, 4.5 Hz, 1H); 13CNM R(101 MHz, CDC13) 8 166.24,166.10, 163.59,
161.14,153.05, 134.73,134.69, 130.40, 130.31,129.35,129.26,128.42,127.44,127.35,
121.41, 118.70, 116.82, 115.80, 115.77, 115.58, 115.55,47.23, 27.41; MS (ESI+) m/z 
calcd 365.12, found [M + H+] 366.20; UPLC retention time: 4.487 min.
21b: 'H  NMR (400 MHz, Acetone-<4) 8 7.90 (d, J =  8.8 Hz, 1H), 7.80 -  7.67 (m, 2H), 
7.60 (ddd, J=  10.9,6.6, 3.8 Hz, 2H), 7.51 (dd, J=  8.4, 6.1 Hz, 1H), 7.43 (dd, J=  8.3, 6.7 
Hz, 2H), 7.29 -  7.06 (m, 4H), 7.02 -  6.85 (m, 2H), 5.28 (d, J =  8.5 Hz, 1H), 4.74 (qd, ./ = 
8.9, 5.8 Hz, 1H), 3.21 (dd, J=  16.3, 9.4 Hz, 1H), 3.13 (dd, J=  16.5, 5.9 Hz, 1H); 13C 
NMR (101 MHz, Acetone-<4) 8 205.25, 166.08, 163.67, 161.26, 154.27, 135.33, 135.30,
30
134.88, 131.08, 129.77, 129.37, 129.28, 128.17, 127.56, 127.01, 120.82, 116.35, 114.89, 
79.49,48.03, 30.91; MS (ESI+) m/z calcd 347.13, found [M + H+] 348.15; UPLC 
retention time: 3.509 min.
21c: NMR (400 MHz, CDC13) 5 7.65 (d, J=  8.4 Hz, 2H), 7.45 -  7.36 (m, 4H), 7.31 -
7.25 (m, 1H), 7.13 -  7.04 (m, 4H), 7.00 (t, J=  7.4 Hz, 1H), 6.39 (d, J=  8.3 Hz, 1H), 5.46 
(d, J=  4.0 Hz, 1H), 4.88 (dq, J=  8.8, 4.5 Hz, 1H), 2.98 (dd, J=  16.7, 4.9 Hz, 1H), 2.86 
(dd, J  = 16.6, 4.4 Hz, 1H); 13C NMR (101 MHz, CDC13) 6 166.25,163.60,161.15,
153.05, 138.02, 134.67, 134.64, 132.47, 130.39, 128.88, 128.43, 128.39, 127.46, 127.37,
121.42, 118.67, 116.82, 115.77, 115.56, 47.29, 27.43; MS (ESI+) m/z calcd 381.09, 
found [M + H+] 381.10; UPLC retention time: 3.831 min.
21d
21d: lH NMR (400 MHz, CDC13) 5 7.35 (dd, J=  8.7, 5.3 Hz, 2H), 7.31 -  7.25 (m, 1H), 
7.14 -  7.02 (m, 4H), 6.98 (t, J=  7.4 Hz, 1H), 5.91 (d, J=  8.2 Hz, 1H), 5.36 (d, J=  3.9 
Hz, 1H), 4.70 (dq, J = 8.2, 4.1 Hz, 1H), 2.86 (dd, 16.7, 4.7 Hz, 1H), 2.72 (dd, J= 
16.7, 4.0 Hz, 1H), 2.01 (s, 3H); 13C NMR (101 MHz, CDC13) 6 169.87, 163.51, 161.07,
153.04, 134.84, 130.41, 128.35, 127.34, 127.27, 121.28, 118.77, 116.74, 115.68, 115.47,
31
46.55, 27.15, 23.43; MS (ESI+) m/z calcd 285.12, found [M + H+] 286.05; UPLC 
retention time: 3.631 min (detected at 230 nm)
21e: ‘H NMR (400 MHz, CDCI3) 6 7.57 (tdd, 7 =  9.2, 5.0, 2.3 Hz, 4H), 7.30 -  7.24 (m, 
1H), 7.21 (d, 7  = 7.3 Hz, 1H), 7.17 -  7.02 (m, 6H), 6.33 (d, 7 =  8.7 Hz, 1H), 5.33 (s, 1H), 
5.00 (ddt, 7 =  8.7,4.8, 2.1 Hz, 1H),3.46 (dd ,7 =  17.0,5.1 Hz, 1H), 3.14 (dd, 7 =  17.0, 2.2 
Hz, 1H); 13C NMR (101 MHz, CDCI3) 5 166.26, 165.98, 163.66, 163.47, 161.21, 153.84, 
133.52,133.49,130.58,130.33,129.20,129.12,127.92,127.41,127.32,122.08,119.38, 
117.15,115.71,115.64, 115.49,115.42,46.52,32.10; MS (ESI+) m/z calcd 365.12, 
found [M + H+] 366.15; UPLC retention time: 3.640 min.
21f
21f: 'H  NMR (400 MHz, CDC13) 6 7.57 (dd, 7  = 8.2, 5.7 Hz, 4H), 7.49 (t, 7 =  7.3 Hz, 
1H), 7.40 (t, 7 =  7.5 Hz, 2H), 7 .3 0 -7 .2 4  (m, 1H), 7.21 (d, 7  = 7.6 Hz, 1H), 7.15 (t,./  = 
8.5 Hz, 2H), 7.10 (d, 7 =  8.1 Hz, 1H), 7.04 (t, 7 =  7.4 Hz, 1H), 6.40 (d, 7 =  8.4 Hz, 1H), 
5.34 (s, 1H), 5 .0 8 -4 .9 7  (m, 1H), 3.46 (dd,7 =  16.9,4.9 Hz, 1H), 3.16 (d d ,7 =  17.1,2.0 
Hz, 1H); 13CNM R(101 MHz, CDCI3) 8 167.32, 163.66, 161.21, 153.87, 134.22, 133.59, 
133.55,131.60,130.57, 128.55,127.89,127.47,127.40, 126.81,122.02,119.44,117.12,
32
115.61, 115.39,46.45, 32.13; MS (ESI+) m/z calcd 347.13, found [M + H+] 348.15; 
UPLC retention time: 3.291 min.
21g: 'H  NMR (400 MHz, CDC13) 5 7.57 -  7.52 (m, 2H), 7.52 -  7.48 (m, 2H), 7.39 -  7.33 
(m, 2H), 7 .3 0 -7 .2 4  (m, 1H), 7.20 (d d ,/=  7.5,1.6 Hz, 1H), 7 .17-7 .11  (m, 2H), 7.10 
(dd, J=  8.3,1.2 Hz, 1H), 7.05 (td, J= 1A, 1A, 1.4 Hz, 1H), 6.34 (d, 8.5 Hz, 1H), 5.33
(s, 1H), 5.00 (ddt, J=  8.8, 5.3, 2.0, 2.0 Hz, 1H), 3.47 (dd, J=  17.0, 5.1 Hz, 1H), 3.14 (dd, 
J=  17.1,2.2 Hz, 1H); 13C NMR (101 MHz, CDC13) 5 166.25,163.66,161.21,153.82, 
137.85, 133.47, 133.45, 132.51, 130.56, 128.80, 128.26, 127.94, 127.40, 127.31, 122.11, 
119.32,117.17, 115.64,115.64,46.56,32.06; MS (ESI+) m/z calcd 381.09, found [M + 
H*] 382.15; UPLC retention time: 3.815 min.
21h
21h: 'H  NMR (400 MHz, CDC13) 5 7.50 (dd ,./=  8.7, 5.4 Hz, 2H), 7.26 (t, J=  7.7 Hz, 
1H), 7.19 (d, J =  7.4 Hz, 1H), 7 .1 7 -7 .1 2  (m, 2H), 7.05 (td, J =  8.3, 1.9 Hz, 2H), 5.77 (d, 
J=  8.8 Hz, 1H), 5.23 (s, 1H), 4.84 (ddt, J =  8.8,4 .7 , 1.9 Hz, 1H), 3.37 (dd, 16.9,5.1 
Hz, 1H), 3.00 (dd, J =  17.1,2.2 Hz, 1H), 1.86 (s, 3H); 13CNM R(101 MHz,CDCl3)5
33
169.84, 163.63, 161.18, 153.87, 133.53, 133.50, 130.59, 127.85, 127.46, 127.37, 121.93,
119.45, 117.09, 115.52, 115.30, 45.78, 32.21, 23.21; MS (ESI+) m/z calcd 285.12, found 
[M + H+] 286.05; UPLC retention time: 2.375 min.
F
Sulfonamide (22)
Table 7: List of sulfonamides and their yields.
Compound Stereochemistry Sulfonyl chloride % yield
22a Trans 4-F Phenyl 87
22b Trans Phenyl 52
22c Trans Me 84
22d Trans 4-C1 Phenyl 55
22e Cis 4-F Phenyl 72
22f Cis Phenyl 82
22g Cis Me 72
22h Cis 4-C1 Phenyl 76
General procedure to synthesize sulfonamides:
Amine (19 or 20) (leq), Sulfonyl Chloride (1.25 eq), thriethyl amine (2eq), and 
dichloromethane were mixed together in a RBF and stirred overnight at room 
temperature. The reaction mixture was diluted in dichloromethane and washed with 
saturated NH4CI solution. The collected organic layer was washed with distilled water, 
then with brine and then dried over anhydrous sodium sulfate. The organic layer was 
concentrated and purified using flash column chromatography (0-60 % gradient of ethyl
34
acetate in hexanes) to afford a white powder. (Refer to Table 7 for yields of all the 
amides that were synthesized)
22a: 'H  NMR (400 MHz, CDCI3) 5 7.83 -  7.72 (m, 2H), 7.30 -  7.13 (m, 5H), 6.99 (td, J  
= 8 .1,7 .5 ,4 .8  Hz, 5H), 5.03 (d, J=  5.9 Hz, 1H), 4.89 (d ,./=  8.1 Hz, 1H), 3.90 (dq, J=  
8.2,5.8 Hz, 1H), 3.01 (dd , J=  16.6,4.9 Hz, 1H), 2.73 (dd, ./=  16.5,6.4 Hz, 1H); 13C 
NMR (101 MHz, CDCI3) 8 166.36, 163.82, 161.12, 153.06, 136.45, 133.87, 130.08, 
129.66, 129.55,128.45, 127.76,127.67,121.55, 118.35,116.65,116.50,116.28,115.83, 
115.62, 51.36,30.21; MS (ESI+) m/z calcd 401.09, found [M + H+] 402.15, [M + NH4+] 
419.20; UPLC retention time: 3.417 min.
22b: ‘H NMR (400 MHz, CDCI3) 6 7.79 -  7.73 (m, 2H), 7.67 -  7.61 (m, 1H), 7.52 (dd, J  
= 8.3, 7.0 Hz, 2H), 7.27 -  7.20 (m, 1H), 7.18 -  7.12 (m, 2H), 7.02 -  6.93 (m, 5H), 5.01 
(d, J=  5.6 Hz, 1H), 4.90 (d, J=  8.3 Hz, 1H), 3.94 -  3.85 (m, 1H), 3.00 (dd, J =  16.5,4.9 
Hz, 1H), 2.73 (dd, J =  16.5, 6.4 Hz, 1H); 13CNM R(101 MHz,CDC13)5  163.75, 161.28, 
153.09, 140.31,133.90,132.79,130.12,129.21,128.37, 127.75,127.66,126.87,121.50,
35
118.45,116.61,115.82,115.61,51.26,30.11; MS (ESI+) m/z calcd 383.10, found [M + 
H+] 384.15, [M + NH4+] 401.25; UPLC retention time: 3.397 min.
22c: ‘H NMR (400 MHz, CDC13) 5 7.71 -  7.63 (m, 2H), 7.51 -  7.43 (m, 2H), 7.24 (td, J  
= 7.5,2.0 Hz, 1H), 7.21 -  7.14 (m, 2H), 6.99 (dtd, J=  13.1,6.8,6.0, 3.2 Hz, 5H), 5.02 (d, 
J=  5.9 Hz, 1H), 4.92 (d, J  = 8.3 Hz, 1H), 3.90 (dq, J=  8.3, 5.8 Hz, 1H), 3.02 (dd,
16.5, 4.9 Hz, 1H), 2.74 (dd, J=  16.5, 6.4 Hz, 1H); 13C NMR (101 MHz, CDC13) 8 
163.82,161.37,153.06, 139.34,138.85,133.81,133.78,130.05,129.44,128.45, 128.27, 
127.78, 127.69,121.55, 118.36,116.65, 115.82,115.61,51.42,30.35; MS (ESI+) m/z 
calcd 417.06, found [M + H+] 418.15, [M + NH4+] 435.25; UPLC retention time: 3.894
22d
22d: ‘H NMR (400 MHz, CDC13) 8 7.46 -  7.39 (m, 2H), 7.28 -  7.22 (m, 1H), 7.17 -  7.09 
(m, 3H), 7.04 -  6.97 (m, 2H), 5.12 (d, J=  6.4 Hz, 1H), 4.69 (d, J=  8.5 Hz, 1H), 4.09 
(dtd, J = 8.8, 6.9, 5.1 Hz, 1H), 3.14 (dd, J=  16.4, 5.1 Hz, 1H), 2.89 (dd, 16.4, 7.1 Hz,
1H), 2.66 (s, 3H); l3C NMR (101 MHz, CDC13) 8 163.94,161.47,153.22, 134.48,
134.44, 129.96,128.42,128.32, 128.23,121.54, 118.64,116.71, 115.91,115.71,51.98,
36
41.78, 31.39; MS (ESI+) m/z calcd 321.08, found [M + i f ]  322.05, [M + NH4+] 339.10; 
UPLC retention time: 2.689 min.
22e
22e: ‘H NMR (400 MHz, CDC13) 5 7.51 -  7.43 (m, 2H), 7.29 -  7.21 (m, 3H), 7.14 (d, J  = 
7.4 Hz, 1H), 7.00 (tt, J =  14.9, 8.1 Hz, 6H), 5.11 (s, 1H), 4.88 (d, J =  8.5 Hz, 1H),3.94 
(ddt, J  = 8.6,4 .4 ,2 .0  Hz, 1H), 3.34 (dd, J=  16.8,4.5 Hz, 1H), 3.13 (dd, J=  16.9,2.4 Hz, 
1H); l3C NMR (101 MHz, CDCI3) 8 166.08,163.54,161.17,153.53,136.00,133.07, 
130.63,129.36,129.28,128.14,127.15,127.06,122.18, 118.29, 116.96,116.06,115.84,
115.40,115.20,51.24,33.39; MS (ESI+) m/z calcd 401.09, found [M + H+] 402.20, [M + 
NH4I  419.20; UPLC retention time: 3.341 min.
22f
22f: ‘H NMR (400 MHz, CDC13) 5 7.57 -  7.46 (m, 3H), 7.35 (d, 7.5 Hz, 2H), 7.24
(ddd, J=  8.9, 5.6, 2.6 Hz, 3H), 7.13 (dd, J  = 7.5, 1.6 Hz, 1H), 7.06 -  6.98 (m, 2H), 6.95 -  
6.87 (m, 2H), 5.11 (s, 1H), 4.84 (d, J=  8.4 Hz, 1H), 3.97 (ddt, J=  8.6, 4.4, 2.1 Hz, 1H), 
3.32 (dd, J=  16.7, 4.5 Hz, 1H), 3.12 (d d ,7 =  16.7, 2.4 Hz, 1H); 13CNM R(101 MHz, 
CDCI3) 8 163.53,161.08,153.59,139.91, 133.01,132.25,130.63,128.84, 128.08,
127.14,127.06,126.61,122.09,118.40,116.92,115.42, 115.20, 51.11, 33.33; MS (ESI+)
37
m/z calcd 383.10, found [M + H*] 384.15, [M + NH4+] 401.15; UPLC retention time:
3.295 min.
22g
22g: JH NMR (400 MHz, CDC13) 5 7.41 -  7.36 (m, 2H), 7.30 -  7.27 (m, 2H), 7.26 -  7.20 
(m, 3H), 7.14 (dd, J=  7.6, 1.5 Hz, 1H), 7.07 -  6.98 (m, 2H), 6.98 -  6.91 (m, 2H), 5.10 (s, 
1H), 4.92 (d, J = 8.4 Hz, 1H), 3.94 (ddt, 8.4, 4.3, 2.1 Hz, 1H), 3.35 (dd, J=  16.7, 4.5 
Hz, 1H), 3.14 (dd, J=  16.9, 2.2 Hz, 1H); 13C NMR (101 MHz, CDC13) 5 163.68, 161.23, 
153.52, 138.87, 138.37, 133.02, 132.98, 130.62, 129.03, 128.14, 128.01, 127.06, 126.99, 
122.19, 118.29, 116.96, 115.40, 115.20,51.30,33.49; MS (ESI+) m/z calcd 417.06, 
found [M + H+] 418.15, [M + NH4+] 435.20; UPLC retention time: 5.055 min.
22h
22h: ]H NMR (400 MHz, CDC13) 5 7.58 -  7.52 (m, 2H), 7.29 -  7.23 (m, 1H), 7.23 -  7.17 
(m, 3H), 7.07 -  7.01 (m, 2H), 5.23 (s, 1H), 4.68 (d, J=  9.5 Hz, 1H), 3.47 (dd, J=  16.7, 
4.8 Hz, 1H), 3.11 (dd, ./ = 16.7, 2.3 Hz, 1H), 2.28 (s, 3H); 13C NMR (101 MHz, CDC13) 5 
163.79, 161.33, 153.53, 134.07, 134.04, 130.72, 128.26, 127.69, 127.62, 122.20, 118.01, 
116.99, 115.71, 115.49, 51.97, 40.99, 34.16; MS (ESI+) m/z calcd 321.08, found [M + 
H+] 322.05, [M + NH4+] 339.10; UPLC retention time: 2.628 min.
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Figure 10: *H NMR of 9 (Route 1)
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Figure 12: *H NMR of 15
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Figure 13: ‘H N M R of 9 (Route 2)
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Figure 14: *H NMR of 16
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Figure 16: 'H NMR of 17
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Figure 18: 'H NMR o f 18
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Figure 20: !H NMR of 19 ( in DMSO)
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Figure 21: 13C NMR of 19 (in DMSO)
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Figure 22: ‘H NMR of 20 (in MeOD)
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Figure 23: 13C NMR of 20 (in MeOD)
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Figure 24: ‘HNMR of 20 ( in DMSO)
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Figure 25: 'H N M R of21a
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Figure 27: lH NMR of 21b (in Acetone-Jö)
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Figure 28: 13C NMR of 21b (in Acetone-ötö)
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Figure 29: 'H NMR of 21c
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Figure 30: 13C N M R of21c
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Figure 31: *HNM Rof21d
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Figure 32: u C N M R of21d
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Figure 33: 'H N M R of21e
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Figure 35: 1H N M R of21f
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Figure 36: 13C N M R of21f
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Figure 37: ‘H N M R of21g
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Figure 39: ‘H NMR of 21h
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Figure 40: 13C N M R of21h
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Figure 41: ‘H NMR of 22a
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Figure 42: 13C N M R of22a
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Figure 43: 1H N M R of22b
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Figure 45: lH  NMR of 22c
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Figure 46: 13C N M R of22c
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Figure 47: 'H NMR of 22d
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Figure 48: 13C N M R of22d
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Figure 49: ‘H NMR of 22e
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Figure 50: l3C N M R of22e
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Figure 51: ‘H N M R of22f
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Figure 52: 13C N M R of22f
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Figure 53: ‘H NMR of 22g
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Figure 54: 13C N M R of22g
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Figure 55: ‘H NMR of 22h
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Figure 56: 13C N M R of22h
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